Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

YM, leading to clinical data from both programs as early as 2010.

A Board meeting of Cytopia unanimously recommended that the acquisition of Cytopia's shares and options is in the best interests of Cytopia shareholders and Cytopia optionholders, and as such those holders should vote in favour of all resolutions to be proposed at the Scheme meetings, subject to there being no Superior Proposal and to the Independent Expert confirming that the Scheme(s) are in the best interests of Cytopia shareholders and Cytopia optionholders as the case may be.

"With their broad international reach and strong cancer focused clinical development expertise, we believe YM is an excellent partner for Cytopia," said Mr. Andrew Macdonald, Chief Executive Officer of Cytopia. "This merger provides the best opportunity available for the continued development and expansion of our lead programs and also provides our shareholders with exposure to a broader portfolio of potential cancer therapies and geographic diversification. We welcome the opportunity to establish a direct YM presence in the Australasian region and contribute to the ongoing success of the merged entity."

"This transaction should deliver an excellent outcome for both groups of shareholders. It is a significant step in developing a wide portfolio of cancer related products to maximise success and to better manage risk," said Mr. David Allan, Chairman and Chief Executive Officer of YM. "We recognise the potential and quality of the Cytopia programs and believe that this combination enhances the opportunity to bring new cancer drugs to international markets."

The Australian operations will be operated under the YM name following completion of the transaction. Pursuant to the provisions of the Agreement, Mr. Bob Watson, Chair of Cytopia will be appointed to the board of YM.

Conference Call

YM BioSciences will host a conference call for analysts and po
'/>"/>

SOURCE Cytopia Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
2. Cytopia Presentation on VDA CYT997 at AACR Conference
3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
4. Cytopia Letter to Progen Shareholders
5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
10. Schering-Plough Shareholders Approve Merger With Merck
11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... BURNIE, Md. , Aug. 19, 2014 ... clinical research industry, recently announced the formation of the ... pleased to announce the addition of Dr. William ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 The ... across a variety of therapeutic areas and set strategic ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... , MONTRÉAL, Jan. 19 /PRNewswire-FirstCall/ - ... established a Special Committee of independent Board members to explore ... a sale of the Company or the sale of all ... be working with management and external consultants to expeditiously make ...
... ... of integration, functionality, innovation, manageability, performance and value provided to end users. , ... (PRWEB) January 19, 2010 ... Silver Award for Virtualization Management. This annual award identifies the companies ...
... NEW HAVEN, Conn. , Jan. 19 ... Richard J. Carroll to the newly created position ... HistoRx over 20 years of sales, marketing, research, and general ... Before joining HistoRx in 2009, he was Vice President of ...
Cached Biology Technology:ConjuChem to evaluate strategic alternatives 2VKernel's Optimization Pack Wins Award In SearchServerVirtualization.Com's 2009 Products of the Year Survey 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
(Date:8/20/2014)... light and its energy is finally utilized for ... devices, mostly build from silicon based semiconductors, also ... for the development of cheaper and renewable photovoltaics ... membrane protein complexes of photosynthesis. Prof. Dr. Matthias ... thermophilic cyanobacteria that live in a hot spring ...
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2
... Inflammation of gum tissues periodontitis is one of ... susceptible to diseases of the circulatory system, rheumatoid arthritis, ... of Jan Potempa, PhD, DSc, professor and academic scholar, ... School of Dentistry, have helped change scientific thinking about ...
... Ore. -- A constellation of defective proteins suspected in causing ... DNA could be the link scientists need to prove a ... broad range of ovarian cancer patients, an Oregon Health & ... results, published this week in PLoS ONE , have ...
... DC - On January 18, 2012, Dr. Peter ... National Homeland Security Research Center in the Office ... Protection Agency, will lead a session titled "National ... national resilience to bioterrorism threats involves maximizing advanced ...
Cached Biology News:UofL researcher earns the Foundation for Polish Science Prize 2Faulty proteins may prove significant in identifying new treatments for ovarian cancer 2